...
首页> 外文期刊>Journal of neonatal-perinatal medicine >Long-term neurodevelopment outcome of caffeine versus aminophylline therapy for apnea of prematurity
【24h】

Long-term neurodevelopment outcome of caffeine versus aminophylline therapy for apnea of prematurity

机译:咖啡因的长期神经发育结果与早产儿呼吸暂停的氨基烯基疗法

获取原文
获取原文并翻译 | 示例

摘要

OBJECTIVE: Methylxanthines are the most commonly prescribed drug in neonatal setups. However, Clinicians show indecision in choosing the right agent for Apnea of Prematurity in most of the developing countries. Present study aimed to compare rate of mortality and survival with normal neurodevelopment outcome at 18 to 24 months of corrected age, between Caffeine- and Aminophylline-treated infants for apnea of prematurity. METHODS: 240 infants were randomly allocated to caffeine and aminophylline for apnea of prematurity during February 2012 to January 2015. Long-term neurodevelopmental assessment was done only from children who had attained corrected age of 18 to 24 months during April 2014 to February 2016. Cognitive, language and motor deficits were assessed by Bayley Scale of infant and toddler development (BSID -III). Postnatal characteristics such as hearing and visual impairments during NICU stay were noted and same were followed up. RESULTS: Infants allocated to caffeine group showed 83% less risk of getting cognitive impairment (RR 0.16; CI 95% range 0.02 to 1.36), 50% less risk of developing motor deficits (RR 0.50; CI 95% range 0.12 to 1.95) and 24% less risk of developing language problems (RR 0.76; CI 95% range 0.36 to 1.58). However in all the neurodevelopment domains the difference between groups was not statistically significant. Risk of mortality in caffeine group was 9% less over aminophylline group which was statistically non-significant (RR - 0.92; CI 95% range - 0.45 to 1.84; p = 0.81). Physical growth parameters were found to be similar in both the groups. Risk of developing visual abnormality and hearing impairments was also statistically non-significant between the groups. CONCLUSION: Caffeine and aminophylline showed similar effects in reducing the rate of mortality and improving the survival without neurodevelopment delays; though the clinical significance of caffeine over aminophylline cannot be undermined.
机译:目的:甲基黄嘌呤是新生儿设置中最常规定的药物。然而,临床医生在大多数发展中国家选择呼吸暂停的呼吸暂停的合适代理人的犹豫不决。目前的研究旨在将死亡率和生存率与正常的神经发光成果在矫正年龄的18至24个月内,在咖啡因和氨茶碱治疗的婴儿的呼吸暂停的呼吸暂停之间。方法:2012年2月至2012年1月,将240名婴儿随机分配给咖啡因和氨基氨基呼吸暂停的呼吸暂停症。只有2014年4月到2016年2月达到18至24个月的较正年龄为18至24个月的儿童进行了长期神经发育评估。认知拜访婴儿和幼儿开发(BSID -III)评估了语言和电机缺陷。 NICU住院期间听力和视觉损伤等后期特征被注意到,随访了。结果:分配给咖啡因组的婴儿表现出83%的认知障碍风险减少(RR 0.16; CI 95%范围0.02至1.36),开发电机缺陷的风险减少(RR 0.50; CI 95%范围0.12至1.95)和表现语言问题的风险减少24%(RR 0.76; CI 95%范围0.36至1.58)。然而,在所有神经发育域中,组之间的差异在统计学上没有统计学意义。在统计学上非显着(RR - 0.92; CI 95%范围 - 0.45至1.84; p = 0.81),咖啡因组死亡率的风险降低9%。发现物理生长参数在两组中都有相似。发展视觉异常和听力障碍的风险在群体之间也存在统计学上不可思议。结论:咖啡因和氨基吡咯表现出类似的效果降低死亡率并改善没有神经发育延误的生存;虽然咖啡因对氨基啉基的临床意义不能破坏。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号